A

Aclaris Therapeutics
D

ACRS

1.44500
USD
-0.01
(-0.34%)
مغلق
حجم التداول
11,868
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
156,466,390
أصول ذات صلة
A
ADAP
0.01110
(4.62%)
0.25130 USD
A
ARWR
-0.120
(-0.71%)
16.790 USD
A
ATRA
0.39000
(4.74%)
8.62000 USD
C
CORT
1.580
(2.21%)
72.970 USD
C
CRIS
0.06000
(3.47%)
1.79000 USD
C
CRSP
0.455
(0.88%)
52.120 USD
F
FATE
0.02000
(1.80%)
1.13000 USD
ICLR
ICLR
-0.832
(-0.55%)
150.070 USD
K
KURA
0.04000
(0.69%)
5.85000 USD
V
VKTX
0.430
(1.55%)
28.150 USD
X
XNCR
0.09500
(1.14%)
8.40000 USD
المزيد
الأخبار المقالات

العنوان: Aclaris Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.